Takeda Pharma is positioning itself to take over stem cell production in Europe from its partner TiGenix by 2021 after Swissmedic accepted for review the file…

Takeda has been eyeing India’s vaccine market since at least 2015, and the idea has come to fruition in the form of two licensing deals.

Bristol-Myers Squibb will unload an API plant in Ireland to a South Korean company with large aspirations in contract manufacturing.

Lingering regulatory problems at the Sun Pharma plant Halol, India, have contributed to a $14.1 billion slide in founder Dilip Shanghvi’s net worth.

Japan’s Sawai is following other drugmakers by establishing a U.S. manufacturing beachhead by acquiring a U.S. generics operation.

A month after Daiichi Sankyo announced plans for a major investment in cancer drug production, Japanese compatriot Otsuka said it is planning to do the same…

Sun Pharma has suffered a gut-wrenching drop in its sales in the U.S. as ongoing regulatory restraints for Sun Pharma’s key API plant in India, along with…

Earlier this month, the FDA banned all products being shipped to the U.S. by a Chinese API maker, and a new warning letter explains why. It appears the…